ASND analyst estimates
Ascendis Pharma (ASND) analyst ratings, the average price target and its range, and every firm's latest call.
ASND analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 26, 2026 | Canaccord Genuity | Ascendis Pharma initiated with a Hold at Canaccord | $268.00 |
| Oct 15, 2026 | UBS | Ascendis Pharma assumed with a Buy at UBS | $269.00 |
| Sep 16, 2026 | UBS | H.C. Wainwright Reiterates Buy Rating on Ascendis Pharma (ASND) | $344.00 |
| Sep 15, 2026 | Raymond James | Raymond James Downgrades Ascendis Pharma (ASND) to Outperform | $287.00 |
| Sep 10, 2026 | H.C. Wainwright | H.C. Wainwright Reiterates Buy Rating on Ascendis Pharma (ASND) | $344.00 |
| Sep 1, 2026 | Morgan Stanley | Ascendis Pharma price target lowered to $273 from $275 at Morgan Stanley | $273.00 |
| Sep 1, 2026 | Oppenheimer | Ascendis Pharma (ASND) PT Raised to $312 at Oppenheimer | $312.00 |
| Aug 31, 2026 | UBS | H.C. Wainwright Reiterates Buy Rating on Ascendis Pharma (ASND) | $345.00 |
| Aug 31, 2026 | Stifel Nicolaus | Ascendis Pharma price target lowered to $326 from $328 at Stifel | $326.00 |
| Aug 31, 2026 | Jefferies | Ascendis Pharma price target lowered to $330 from $333 at Jefferies | $330.00 |
| Aug 27, 2026 | H.C. Wainwright | Ascendis Pharma initiated with a Buy at H.C. Wainwright | $345.00 |
| Aug 18, 2026 | BMO Capital | Ascendis Pharma initiated with an Outperform at BMO Capital | $319.00 |
| Aug 14, 2026 | Barclays | Ascendis Pharma price target lowered to $329 from $345 at Barclays | $329.00 |
| Aug 14, 2026 | RBC Capital | Ascendis Pharma price target raised to $290 from $280 at RBC Capital | $290.00 |
| Aug 13, 2026 | Jefferies | Ascendis Pharma (ASND) PT Raised to $333 at Jefferies | $333.00 |
- 15 firms rate ASND: 15 buy, 0 hold, 0 sell.
- The average price target is $304.27 from 11 analysts, from $268.00 to $344.00.
Updated 2026-11-03 00:00 UTC